A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): Results from the Myeloma X (Intensive) Trial.
Cook, G Williams, C Cairns, D Hockaday, A Cavanagh, J Snowden, J Parrish, C Yong, K Cavet, James Hunter, H
Cook, G
Williams, C
Cairns, D
Hockaday, A
Cavanagh, J
Snowden, J
Parrish, C
Yong, K
Cavet, James
Hunter, H
Citations
Altmetric:
Abstract
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): Results from the Myeloma X (Intensive) Trial. 2016, 173:5-6 Br J Haematol